Alvocidib Biomarker-driven Phase 2 AML Study

NCT02520011 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

104

Enrollment

INDUSTRY

Sponsor class

Stopped Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Alvocidib
DRUG: Cytarabine
DRUG: Mitoxantrone

Sponsor

Sumitomo Pharma America, Inc.